Live Analyst Rating Changes 1527 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Toung
ARG
David Toung
Wall Street Analyst
★★★☆☆
#893
on 13Foresight · ranked by our own returns
53%
Success Rate
+5.3%
Average Return
24 of 45 calls profitable · -6.7% vs benchmark
📈 Across the calls we could measure, roughly 53% of David Toung's ratings turned a profit when each position was held for 1 year — averaging +5.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 5 Hold 0 Sell
David's Stock Coverage 40 ratings · 2026-06-21
Company Date Position Consensus Price Target 1-Yr Return
IART
Integra Lifesciences
Jun 17, 2026 BUY Buy
+136.2% avg upside
21 analysts
$25.00
42.18% Upside
+0.0%
LH
Labcorp Holdings
Jun 02, 2026 BUY Strong Buy
+1.8% avg upside
36 analysts
$310.00
21.25% Upside
-0.7%
IQV
IQVIA Holdings
May 29, 2026 BUY Strong Buy
+34.5% avg upside
38 analysts
-2.1%
EW
Edwards Lifesciences
May 21, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
+4.2%
PFE
Pfizer
May 06, 2026 BUY Buy
+34.2% avg upside
45 analysts
$35.00
38.92% Upside
-3.4%
BSX
Boston Scientific
Apr 24, 2026 BUY Strong Buy
+72.9% avg upside
38 analysts
$95.00
109.71% Upside
-27.0%
DHR
Danaher
Apr 23, 2026 BUY Strong Buy
+21.9% avg upside
45 analysts
$230.00
29.86% Upside
-0.4%
UNH
UnitedHealth
Apr 21, 2026 BUY Strong Buy
+2.3% avg upside
35 analysts
$400.00
0.29% Downside
+16.5%
MDT
Medtronic
Apr 06, 2026 BUY Buy
+23.5% avg upside
38 analysts
$115.00
44.92% Upside
-8.0%
BDX
Becton Dickinson
Mar 20, 2026 BUY Buy
+35.5% avg upside
25 analysts
$180.00
25.03% Upside
-5.9%
COR
Cencora
Mar 17, 2026 BUY Buy
+14.6% avg upside
43 analysts
$400.00
47.19% Upside
-17.0%
GEHC
GE Healthcare Technologies Inc
Mar 03, 2026 BUY Strong Buy
+36.0% avg upside
20 analysts
$95.00
54.19% Upside
-21.1%
SOLV
Solventum Corporation
Dec 12, 2025 BUY Buy
+14.1% avg upside
15 analysts
-9.1%
HUM
Humana
Dec 08, 2025 HOLD Buy
-11.2% avg upside
34 analysts
+42.4%
TECH
Bio-Techne
Nov 20, 2025 BUY Strong Buy
+38.3% avg upside
21 analysts
$68.00
17.38% Upside
-4.3%
CRL
Charles River Labs
Nov 17, 2025 BUY Strong Buy
+11.9% avg upside
34 analysts
$200.00
8.18% Upside
+12.0%
TMO
Thermo Fisher
Oct 28, 2025 BUY Strong Buy
+26.8% avg upside
38 analysts
$610.00
31.26% Upside
-17.0%
JNJ
Johnson & Johnson
Oct 14, 2025 BUY Strong Buy
-3.5% avg upside
36 analysts
$210.00
8.09% Downside
+21.8%
MCK
McKesson
Aug 20, 2025 BUY Strong Buy
-2.2% avg upside
27 analysts
$775.00
3.22% Upside
+10.6%
ELV
Elevance Health
Jul 21, 2025 HOLD Strong Buy
+10.9% avg upside
32 analysts
+43.5%
ABT
Abbott Laboratories
Apr 21, 2025 BUY Strong Buy
+31.2% avg upside
35 analysts
$150.00
69.70% Upside
-27.2%
TDOC
Teladoc
Mar 26, 2025 HOLD Buy
+256.9% avg upside
37 analysts
-36.1%
SYK
Stryker
Feb 03, 2025 BUY Strong Buy
+24.0% avg upside
36 analysts
$450.00
46.27% Upside
-6.9%
DGX
Quest Diagnostics
Oct 24, 2024 BUY Buy
-12.4% avg upside
33 analysts
$175.00
10.20% Downside
+17.5%
PH
Parker Hannifin
Aug 15, 2024 BUY Strong Buy
-7.9% avg upside
29 analysts
+24.8%
HCA
HCA Healthcare
Aug 01, 2024 BUY Buy
+14.7% avg upside
35 analysts
-1.1%
ISRG
Intuitive Surgical
Jul 23, 2024 BUY Strong Buy
+29.4% avg upside
36 analysts
$520.00
27.85% Upside
+10.3%
ZBH
Zimmer Biomet Holdings
May 20, 2024 BUY Buy
+27.6% avg upside
37 analysts
$150.00
70.52% Upside
-19.2%
LLY
Eli Lilly & Co
Feb 07, 2024 BUY Strong Buy
-10.5% avg upside
47 analysts
$770.00
29.94% Downside
+21.9%
AMGN
Amgen
Nov 06, 2023 BUY Buy
-11.6% avg upside
57 analysts
$300.00
11.20% Downside
+21.5%
MRK
Merck & Company
Jun 06, 2023 BUY Strong Buy
+10.7% avg upside
43 analysts
$125.00
9.72% Upside
+21.9%
GILD
Gilead Sciences
Jan 28, 2022 BUY Strong Buy
-4.8% avg upside
66 analysts
$75.00
39.44% Downside
+27.1%
BMY
Bristol-Myers Squibb
Nov 01, 2021 HOLD Buy
+9.1% avg upside
42 analysts
+36.5%
ABBV
AbbVie
Aug 05, 2021 BUY Buy
+2.9% avg upside
43 analysts
$140.00
35.29% Downside
+24.8%
NVS
Novartis
Mar 10, 2021 HOLD Hold
-7.7% avg upside
24 analysts
+2.7%
CAH
Cardinal Health
Aug 27, 2019 HOLD Strong Buy
-12.7% avg upside
29 analysts
+25.7%
BIIB
Biogen
Feb 16, 2018 HOLD Strong Buy
+25.1% avg upside
51 analysts
+14.1%
MDRX
Veradigm
Oct 21, 2016 BUY Buy
+207.0% avg upside
22 analysts
$19.00
295.83% Upside
+12.8%
BAX
Baxter International
Aug 15, 2016 HOLD Hold
+49.6% avg upside
23 analysts
+27.0%
NSA
National Storage Affiliates
Apr 05, 2016 HOLD Hold
-15.9% avg upside
25 analysts
$21.00
52.80% Downside
+26.1%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
David Toung — Frequently Asked Questions
How accurate are David Toung's stock ratings?
Based on the calls 13Foresight could measure, about 53% of David's ratings were profitable over a one-year hold, with an average return of +5.3% per rating, or -3.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Toung is currently ranked #893 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on IART, LH, IQV, EW, PFE, BSX, DHR, UNH, MDT, BDX, COR, GEHC and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.